iOmx Therapeutics AG
iOmx Therapeutics is a clinical- stage biopharmaceutical company focused on developing first-inclass cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated nextgeneration immune checkpoints and is advancing a clinical pipeline of promising drug candidates that have the potential to address cancers which are resistant to current immunotherapies. The company’s lead candidate OMX- 0407 targeting SIK3, an immune protective kinase in multiple solid tumors, is currently being investigated in a Phase I clinical study.
Founded in 2016, based on the work of its scientific founders Philipp Beckhove MD, and Nisit Khandelwal Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, including Wellington Partners, Sofinnova Partners, M Ventures, MIG Capital and Athos Biopharma. iOmx is based in Martinsried/ Munich, Germany.